ALX Oncology Holdings Inc (ALXO)
1.29
-0.04
(-3.01%)
USD |
NASDAQ |
Nov 15, 16:00
1.29
0.00 (0.00%)
After-Hours: 20:00
ALX Oncology Holdings Free Cash Flow (Quarterly): -25.52M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -25.52M |
June 30, 2024 | -26.66M |
March 31, 2024 | -38.07M |
December 31, 2023 | -39.83M |
September 30, 2023 | -29.86M |
June 30, 2023 | -33.45M |
March 31, 2023 | -28.51M |
December 31, 2022 | -21.06M |
September 30, 2022 | -31.08M |
June 30, 2022 | -17.26M |
March 31, 2022 | -21.26M |
December 31, 2021 | -22.01M |
Date | Value |
---|---|
September 30, 2021 | -25.25M |
June 30, 2021 | -20.62M |
March 31, 2021 | -5.142M |
December 31, 2020 | -13.63M |
September 30, 2020 | -9.558M |
June 30, 2020 | -6.163M |
March 31, 2020 | -8.973M |
December 31, 2019 | -2.812M |
September 30, 2019 | -3.186M |
June 30, 2019 | -4.625M |
March 31, 2019 | -3.979M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-39.83M
Minimum
Dec 2023
-2.812M
Maximum
Dec 2019
-21.33M
Average
-21.63M
Median
Free Cash Flow (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 200.30M |
Neurocrine Biosciences Inc | 149.90M |
Eton Pharmaceuticals Inc | 1.255M |
Verve Therapeutics Inc | -40.54M |
Immuneering Corp | -11.56M |